Price:

SCIENCE

Altos Labs pivots longevity from immortality to curable diseases

Tuesday, May 19, 2026 · from 2 podcasts
Peter Attia DriveThe Daily
  • Billionaire-funded labs reframe cellular reprogramming as disease reversal, not eternal life.
  • Top physicians warn genetic hype oversells actionable risk while overlooking dangerous gaps.
  • Consumer tests miss thousands of deadly mutations, creating a false sense of security.

In the sprawling San Diego facility of Altos Labs, miniature human brains and beating hearts grow from stem cells. Susan Dominus observed these 'organoids' on The Daily, as billionaires like Jeff Bezos poach top scientists to build 'virtual cells' and run simulations that would take decades in a traditional lab.

But CEO Hal Barron is pivoting away from the immortality claims that have historically dogged the field. Dominus noted Barron frames the victory as extending ovarian viability or curing glaucoma - aiming to 'die healthy' rather than live forever. The science backing this shift is substantial: in 2016, Juan Carlos Izpisúa Belmonte applied a reduced dose of Nobel-winning reprogramming factors to fast-aging mice. They lived longer, looked younger, and healed faster without triggering the monstrous tumors of earlier attempts.

"Altos CEO Hal Barron is taking the opposite track, focusing on incremental gains rather than a 150-year lifespan."

- Susan Dominus, The Daily

This pragmatic reframing faces skepticism from within medicine. On The Peter Attia Drive, physician Peter Attia warns that public excitement around genetic and cellular manipulation often overlooks critical limitations. For most chronic diseases, he argues, measuring observable biological output - like artery imaging or insulin resistance - is more actionable than genetic predictions. The Human Genome Project, completed in 2003, failed to deliver on broad promises of predicting complex diseases.

Attia separates test utility into a matrix of effect size and actionability. High-penetrance mutations like BRCA1, which dictate specific surgeries, sit in the top-right corner. At the opposite end, he dismisses functional medicine staples like MTHFR, which appear in up to 40% of the population and rarely drive meaningful disease. Using them to justify bespoke supplement protocols is often more about marketing than biology.

The gap between consumer perception and clinical reality is dangerous. Attia warns that products like 23andMe scan for common 'snips' rather than sequencing full genes. A consumer test might check only three BRCA mutations out of thousands of pathogenic variants, creating a false negative.

"If a result doesn't change a medical decision, the test is noise."

- Peter Attia, The Peter Attia Drive

The billionaires' race is now between two visions: one aiming for incremental, disease-specific victories to avoid regulatory backlash, and another, embodied by controversial figures like Harvard's David Sinclair, still branded with immortality hype. The field's ultimate impact may depend less on cellular reprogramming and more on whether it can reprogram its own public narrative.

#Longevity#Health#Startups
Science

Source Intelligence

- Deep dive into what was said in the episodes

The Peter Attia Drive
The Peter Attia Drive

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results • May 18

  • Peter Attia says genetic testing is often oversold; the core question is not 'should I test' but what specific health question a test could answer and whether genetics is the best tool.
  • Peter Attia argues the Human Genome Project, completed in 2003, failed to deliver on broad promises of predicting complex diseases. He notes the genome's complexity: 20,000 genes, 6 billion base pairs, and 5 million single nucleotide variants.
  • Attia states most genetic risks are probabilistic, not deterministic. High-penetrance mutations like Huntington's disease are the exception. Most common diseases involve many genes layered on environment, behavior, and chance.
  • Peter Attia lists four limitations of genetic testing: genetic data are often probabilistic; our ability to interpret lags data generation; phenotype measurement is often more informative; and results can carry psychological weight.
  • Attia says for atherosclerotic cardiovascular and metabolic disease, routine genetic testing is weak. He argues measuring phenotypes like blood pressure, lipids, and insulin resistance is more actionable than genetic estimates.
  • Peter Attia cites exceptions in cardiometabolic disease: familial hypercholesterolemia for confirming diagnosis, SCARB1 mutations that mask cardiovascular risk on a standard lipid panel, and cases where genetic data shifts patient behavior.
  • Attia says only about 5% of cancers are attributable to inherited germline mutations. He notes hereditary cancer panels for high-penetrance genes like BRCA1/2 and Lynch syndrome are highly actionable, changing screening and management.
  • Peter Attia warns consumer genetic tests often assess only a few pathogenic mutations; a negative BRCA result on 23andMe does not rule out thousands of other known pathogenic variants. Clinical-grade panel testing is needed for risk assessment.
  • Peter Attia says APOE4 is the strongest common genetic risk factor for Alzheimer's, with homozygotes having up to 15 times higher risk. He notes it is not deterministic, with about 50% of Alzheimer's patients not carrying an APOE4 allele.
  • Attia is skeptical of functional medicine panels like MTHFR testing. He notes up to 40% of the population carries these common variants, and they rarely drive meaningful disease or justify specialized supplement protocols.
  • Peter Attia highlights pharmacogenetics as a genuinely useful area. Examples include CYP2C19 testing for Plavix activation, where 10% of people cannot convert it, and HLA-B*58 testing to avoid life-threatening reactions to allopurinol.
  • Attia ranks test utility on two axes: effect size of the variant and clinical actionability. Hereditary cancer panels and pharmacogenetics score high, while consumer SNP tests for MTHFR score low on both dimensions.
  • Peter Attia categorizes genetic tests from narrowest to broadest: single-gene tests, genotyping arrays (SNP tests), gene panels, whole exome sequencing, and whole genome sequencing. He advises matching the test type to the specific clinical question.
  • Attia recommends using CLIA-certified labs with domain expertise for clinically meaningful tests. He stresses understanding a test's coverage, privacy policies, and the meaning of a negative result before ordering.
  • Peter Attia frames the value of a genetic result around the question 'what now?'. He says results should either confirm a diagnosis, identify a novel actionable risk, add context, or inform planning - otherwise the test lacked purpose.
#Longevity#Biology
The Daily
The Daily

Can We Reverse Aging? • May 17

  • Longevity science focuses on cellular rejuvenation - the idea that aged cells can be made to function like younger cells. Susan Domonius points to embryos as proof, noting they shed inherited aging markers shortly after fertilization.
  • Shinya Yamanaka won the Nobel Prize in 2006 for reverting aged mouse skin cells to embryonic form using powerful genes. Early attempts to apply these Yamanaka factors to mice caused monstrous tumors, as cells became unspecialized and developed fatal teratomas.
  • Juan Carlos Izpisua Belmonte tweaked the Yamanaka formula, applying a reduced dose to fast-aging mice. The mice lived longer, looked younger with less gray fur, had stronger muscles, healed faster, and became friscier - lab technicians thought they were replaced.
  • David Sinclair, a Harvard genetics professor, is a controversial figure in longevity research. Domonius notes colleagues criticize him for overselling promises, circulating unsupported claims about reversing aging in dogs, and co-founding a wellness platform with non-mainstream practices.
  • Sinclair’s key breakthrough involved dropping the most cancer-prone Yamanaka factor and using only three to restore vision in blinded mice without causing cancer. Life Biosciences, his biotech, has FDA approval for human safety trials targeting glaucoma and nystagmus.
  • Billionaires are the primary backers of longevity science. Sam Altman invested roughly $200 million in Retro Biosciences. Jeff Bezos is a major investor in Altos Labs, the largest biotech startup launch in history.
  • Altos Labs recruited top scientists like Belmonte by offering million-dollar salaries, triggering a major academic migration to private industry. The company focuses on predictive research using human organoids and AI-driven virtual cells to bypass unreliable mouse models.
  • Hal Barron, Altos Labs CEO, distances the company from extreme longevity promises like living to 150. Domonius says Barron aims for reasonable goals, such as extending human health by a few years or preserving ovary function, which he considers revolutionary.
  • The realistic expectation for cellular rejuvenation is treating specific diseases like glaucoma within a decade, not dramatically expanding lifespan. Domonius argues the goal is curing disease to reduce suffering and extend healthy years, not achieve radical longevity.
  • Domonius notes billionaires investing in longevity R&D hope to profit, which requires treatments becoming widely available. She acknowledges this mirrors the pharmaceutical industry's profit-driven model, but the convergence with tech billionaires raises uncharted questions about control and privacy.
  • Extending lifespan raises economic and philosophical issues. Social Security isn't designed for people living to 110. Domonius says if people are healthier longer, they might remain active and fill roles amid population decline, reducing pressure on young caregivers.
  • Hal Barron stated we already know how to reverse aging through diet, exercise, sleep, and sociability. Domonius points to GLP-1 drugs as evidence that behavioral solutions are insufficient, arguing accessible medical interventions could transform health for those in food deserts or under stress.
#Longevity#Biology#Health#Startups#AI Infrastructure

Related Stories